Try our beta test site

A Multicenter Study for Pre-Surgical Weight Loss

This study has been completed.
Information provided by:
GI Dynamics Identifier:
First received: January 26, 2009
Last updated: April 19, 2010
Last verified: April 2010

The purpose of the study is to evaluate the safety and initial efficacy of the GI Sleeve™ device in patients who require weight loss prior to their Bariatric surgery.

It is a randomized, prospective controlled, open label, pilot study of 40 patients. Thiry patients will receive an implant of the GI Sleeve™ device and the other 10 patients will receive the principle investigator's standard of care diet program. All patients will be treated for 12 weeks with the exception of the last 10 device patients who will continue to 24 weeks if the principle investigator determines that it is safe and in their best interest to continue.

The primary efficacy endpoint is:

  • Assessment of the difference in % excess weight loss between the 2 groups

Secondary endpoints are:

  • Resolution or Improvement in type II Diabetic status as defined as:
  • Resolution = patient is off their diabetes medication and has normal diabetic blood parameters (fasting glucose)
  • Improvement = normalizing diabetic blood parameters (fasting glucose) and/or a reduction in dosing or frequency of their diabetic medication
  • The percent of patients who achieve at least a 10% excess weight loss will be calculated as a secondary outcome.

Condition Intervention
Device: GI Sleeve™ (EndoBarrier)
Other: Diet + Lifestyle Counseling

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Pilot Efficacy Study of the GI Sleeve™ for Pre-Surgical Weight Loss

Resource links provided by NLM:

Further study details as provided by GI Dynamics:

Primary Outcome Measures:
  • Assessment of the difference in percent excess weight loss between the device group and a non-device, medically supervised diet control group [ Time Frame: 12-24 weeks ]

Secondary Outcome Measures:
  • The proportion of subjects achieving at least a 10% excess weight loss [ Time Frame: 12-24 weeks ]
  • Resolution/improvement of Type 2 Diabetes defined as: Resolution: Subject is off diabetes medication, has normal fasting glucose Improvement: Normalizing fasting glucose and/or a reduction in dosing or frequency of diabetic medication [ Time Frame: 12-24 weeks ]

Enrollment: 40
Study Start Date: January 2007
Study Completion Date: September 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
GI Sleeve™ + Diet + Lifestyle counseling
Device: GI Sleeve™ (EndoBarrier)
Monthly visits
Other Name: GI EndoBarrier Gastrointestal Liner
Diet + Lifestyle counseling
Other: Diet + Lifestyle Counseling
Monthly Visits
Other Name: Diet Control


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years and < 55 years - Male or Female
  • BMI > 35 with significant comorbidities (i.e. hypertension, or hyperlipidemia, or diabetes) or > 40 BMI <60 (with or without a co-morbid condition)
  • History of failure with nonsurgical weight loss methods
  • Candidates for Roux-en-Y gastric bypass
  • Patients willing to comply with study requirements
  • Patients who have signed an informed consent form

Exclusion Criteria:

  • Patients requiring prescription anticoagulation therapy
  • Patients with iron deficiency and iron deficiency anemia
  • Inflammatory bowel disease or condition of the gastrointestinal tract, such as ulcers or Crohn's disease
  • Treatment represents an unreasonable risk to the patient
  • Pancreatitis or other serious organic conditions
  • Symptomatic coronary artery disease or pulmonary dysfunction
  • Patients with known gallstones prior to implant
  • Known infection at the time of implant
  • Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
  • Congenital or acquired anomalies of the GI tract such as atresias or stenoses
  • Pregnant or has the intention of becoming pregnant in the next 12 months
  • Unresolved alcohol or drug addiction
  • HIV Positive patients
  • Patients with hepatitis B or C
  • Mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement or clinical trial
  • Previous GI surgery that could affect the ability to place the sleeve or the function of the implant.
  • Patients unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period
  • H. pylori positive patients (Note: patients may be enrolled if they had a prior history and were successfully treated)
  • Patients receiving weight loss medications such as Meridia and Xenical
  • Family or patient history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder
  • Patients with GERD
  • Patients with a history of kidney stones
  • Participating in another ongoing investigational clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00830440

University Hospital Maastricht
Maastricht, Netherlands
Sponsors and Collaborators
GI Dynamics
Principal Investigator: Jan Willem Greve, MD Maastricht University Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Jan Willem Greve, MD, University Hospital Maastricht Identifier: NCT00830440     History of Changes
Other Study ID Numbers: 06-4
Study First Received: January 26, 2009
Last Updated: April 19, 2010

Additional relevant MeSH terms:
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms processed this record on March 28, 2017